Arterra Bioscience reports full-year 2023 earnings

Arterra Bioscience (BIT:ARBS) Full Year 2023 Results

Key financial results

• Revenues: EUR 4.72 million (down 1.8% compared to 2022).
• Net profit: EUR 1.08 million (down 24% compared to 2022).
• Profit margin: 23% (down from 29% in fiscal 2022). The decline in margin was mainly due to higher costs.

All numbers shown in the chart above are for the last 12 months (TTM)

Arterra Bioscience shares are up 11% from a week ago.

Risk assessment

You should always think about risk. An example is that we noticed 2 warning signs for Arterra Bioscience you should be aware of this.

Have an opinion on this article? Concerned about the content? contact us with us directly. You can also send an email to editorial-team (at) simplywallst.com.

This article by Simply Wall St is for general information purposes only. We comment based on historical data and analyst forecasts, using only an unbiased methodology, and our articles are not intended to provide financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your objectives or your financial situation. Our goal is to provide you with long-term, focused analysis based on fundamental data. Please note that our analysis may not reflect the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Contact us directly. You can also send an email to [email protected]